Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Liraglutide
Drug ID BADD_D01298
Description Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist[Label,A6932]. Liraglutide is 97% homologous to native human GLP-1 by substituting arginine for lysine at position 34[A6932]. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor[A6932]. Liraglutide was granted FDA approval on Januray 25, 2010[L6070].
Indications and Usage For use in/treatment of diabetes mellitus type 2.
Marketing Status Prescription
ATC Code A10BJ02
DrugBank ID DB06655
KEGG ID D06404
MeSH ID D000069450
PubChem ID 16134956
TTD Drug ID D03GOI
NDC Product Code 66558-0193; 69766-034; 0169-4060; 71796-022; 73569-007; 32861-0003; 50090-4503; 52221-122; 65129-1375; 50090-4257; 70155-003; 50090-2853; 41524-0011; 14403-0009; 76177-118; 0169-2800; 66558-0181; 0420-9006
Synonyms Liraglutide | Victoza | Saxenda | NN 2211 | 2211, NN | NN2211 | NN-2211
Chemical Information
Molecular Formula C172H265N43O51
CAS Registry Number 204656-20-2
SMILES CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O) NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O )NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O )C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O )C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C( CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6) N)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.003--
Alanine aminotransferase increased13.03.01.003--
Amylase13.05.01.010--Not Available
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Angioedema10.01.05.009; 23.04.01.001--Not Available
Anxiety19.06.02.002--
Aspartate aminotransferase increased13.03.01.006--
Asthenia08.01.01.001--Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Blood calcitonin13.10.02.008--Not Available
Blood creatinine increased13.13.01.004--
Blood pressure decreased13.14.03.002--Not Available
Breast cancer21.05.01.003; 16.10.01.001--Not Available
Bronchitis22.07.01.001; 11.01.09.001--
Bronchospasm22.03.01.004; 10.01.03.012--
Cholecystitis acute09.03.01.003--Not Available
Cholestasis09.01.01.001--Not Available
Circulatory collapse24.06.02.001--Not Available
Constipation07.02.02.001--
Dehydration14.05.05.001--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Dry mouth07.06.01.002--
Dysgeusia07.14.03.001; 17.02.07.003--
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages